Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 117.27M | 91.30M | 57.97M | 55.26M | 53.34M |
Gross Profit | 68.22M | 55.47M | 32.14M | 32.49M | 34.39M |
EBITDA | -7.88M | 5.08M | -5.43M | -2.51M | 1.33M |
Net Income | -16.45M | 660.00K | -8.48M | -5.84M | -7.02M |
Balance Sheet | |||||
Total Assets | 93.84M | 92.61M | 60.23M | 54.69M | 41.47M |
Cash, Cash Equivalents and Short-Term Investments | 6.20M | 5.71M | 20.30M | 18.24M | 2.34M |
Total Debt | 35.14M | 23.56M | 17.07M | 16.84M | 18.54M |
Total Liabilities | 50.87M | 41.26M | 26.06M | 23.81M | 26.95M |
Stockholders Equity | 42.96M | 51.35M | 34.17M | 30.88M | 14.51M |
Cash Flow | |||||
Free Cash Flow | -16.01M | -10.97M | -7.11M | -1.68M | -2.28M |
Operating Cash Flow | -11.90M | -9.52M | -5.34M | 439.00K | -731.00K |
Investing Cash Flow | -3.73M | -24.78M | -1.56M | -1.89M | -1.30M |
Financing Cash Flow | 16.07M | 19.69M | 9.02M | 17.50M | -861.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $100.71M | 13.06 | 5.00% | ― | 0.29% | -22.13% | |
62 Neutral | $75.55M | ― | -267.29% | ― | 12.78% | 15.53% | |
61 Neutral | $85.04M | ― | -130.26% | ― | -6.27% | 16.76% | |
58 Neutral | $88.91M | ― | -52.88% | ― | ― | 29.64% | |
54 Neutral | $87.77M | ― | -26.20% | ― | 20.81% | -498.66% | |
52 Neutral | $7.61B | 0.04 | -62.94% | 2.44% | 16.14% | 0.33% | |
44 Neutral | $92.42M | ― | -117.76% | ― | ― | 15.22% |
On July 7, 2025, Xtant Medical Holdings announced agreements to sell its Coflex and CoFix spinal implant assets and international hardware business to Companion Spine, LLC for approximately $19.2 million. The transaction, expected to close in the third quarter of 2025, aims to reduce Xtant’s debt and improve liquidity. The sale will allow Xtant to focus on its core orthobiologics business, while Companion Spine will enhance its product portfolio and global presence in spine care. The deal involves risks, including potential delays and financing uncertainties, which could impact Xtant’s operations and financial condition.
The most recent analyst rating on (XTNT) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Xtant Medical Holdings stock, see the XTNT Stock Forecast page.